<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560336</url>
  </required_header>
  <id_info>
    <org_study_id>NN8022-4380</org_study_id>
    <secondary_id>U111-1199-8606</secondary_id>
    <nct_id>NCT03560336</nct_id>
  </id_info>
  <brief_title>A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.</brief_title>
  <official_title>Prospective, Multicentre, Open-label, Single-arm, Non-interventional Regulatory Post-marketing Surveillance(rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda® (Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect information about the safety and effectiveness of
      Saxenda® in obese patients and overweight patients with obesity-related comorbidities. The
      participant will attend the clinic or hospital according to usual practice and receive
      medical care, as agreed with the study doctor. The participation is expected to be
      approximately for 26 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 21, 2018</start_date>
  <completion_date type="Anticipated">October 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) by preferred term (PT)</measure>
    <time_frame>From baseline to week 13 (± 3 weeks)</time_frame>
    <description>Count of events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) by preferred term (PT)</measure>
    <time_frame>From baseline to week 26 (± 3 weeks)</time_frame>
    <description>Count of events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse drug reaction (ADRs)</measure>
    <time_frame>From baseline to week 13 (± 3 weeks)</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse drug reaction (ADRs)</measure>
    <time_frame>From baseline to week 26 (± 3 weeks)</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events (SAEs) and serious adverse drug reations (SADRs)</measure>
    <time_frame>From baseline to week 13 (± 3 weeks)</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events (SAEs) and serious adverse drug reations (SADRs)</measure>
    <time_frame>From baseline to week 26 (± 3 weeks)</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unexpected AEs and unexpected ADRs</measure>
    <time_frame>From baseline to week 13 (± 3 weeks)</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unexpected AEs and unexpected ADRs</measure>
    <time_frame>From baseline to week 26 (± 3 weeks)</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unexpected SAEs and unexpected SADRs</measure>
    <time_frame>From baseline to week 13 (± 3 weeks)</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unexpected SAEs and unexpected SADRs</measure>
    <time_frame>From baseline to week 26 (± 3 weeks)</time_frame>
    <description>Count of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of liraglutide after administration initiation</measure>
    <time_frame>week 13 (± 3 weeks)</time_frame>
    <description>Measured in mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of liraglutide after administration initiation</measure>
    <time_frame>week 26 (± 3 weeks)</time_frame>
    <description>Measured in mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight loss (%) from week 0 to week 13</measure>
    <time_frame>Week 0, week 13</time_frame>
    <description>Measured in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight loss (%) from week 0 to week 26</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>Measured in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight loss (kg) from week 0 to week 13</measure>
    <time_frame>Week 0, week 13</time_frame>
    <description>Measured in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight loss (kg) from week 0 to week 26</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>Measured in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients losing at least 5% of week 0 body weight at week 13</measure>
    <time_frame>Week 0, week 13</time_frame>
    <description>Proportion of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients losing at least 5% of week 0 body weight at week 26</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>Proportion of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients losing more than 10% of week 0 body weight at week 13</measure>
    <time_frame>Week 0, week 13</time_frame>
    <description>Proportion of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients losing more than 10% of week 0 body weight at week 26</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>Proportion of patients</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Overall Population</arm_group_label>
    <description>Patients will be treated with commercially available liraglutide 3.0 mg according to routine clinical practice at the discretion of the treating physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Patients will initiate treatment with liraglutide according to the approved label in Korea. Patients will initiate 0.6 mg daily and weekly increase the dose by 0.6 mg until reaching 3.0 mg daily. Patients will then continue to stay on 3.0 mg/day (total treatment duration: 26 weeks).</description>
    <arm_group_label>Overall Population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Obese patients and overweight patients with obesity-related comorbidities
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: - The decision to initiate treatment with commercially available
        Saxenda® has been made by the patient/Legally Acceptable Representative (LAR) and the
        physician before and independently from the decision to include the patient in this study -
        Informed consent obtained before any study-related activities Study-related activities are
        any procedures that are carried out as part of the study, including activities to determine
        suitability for the study - Male or Female of Native Korean, age greater than or equal to
        18 years who is scheduled to start treatment with Saxenda® based on the clinical judgment
        of physician as specified in the Korean-Prescribing Information (local label) Exclusion
        Criteria: - Patients who are or have previously been on Saxenda® therapy - Known or
        suspected hypersensitivity to Saxenda® , the active substance or any of the excipients -
        Previous participation in this study. Participation is defined as having given informed
        consent in this study - Treatment with any investigational drug within 30 days prior to
        enrolment into the study - Female patient who is pregnant, breast-feeding, or intends to
        become pregnant and is of child-bearing potential and not using adequate contraceptive
        methods (adequate contraceptive measures as required by Korea regulation or practice) -
        Mental incapacity, unwillingness, or language barriers precluding adequate understanding or
        cooperation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor and Disclosure (1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ansan</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Busan</city>
        <zip>47360</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Busan</city>
        <zip>48107</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Busan</city>
        <zip>49267</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Daejeon</city>
        <zip>302-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Daejeon</city>
        <zip>361-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gwangju</city>
        <zip>12756</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>10475</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>13120</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>21431</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seongnam-si</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>06135</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>133-792</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>6601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Suwon</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Yangsan</city>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 6, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://www.novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

